The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Current strategies in extending half-lives of therapeutic proteins
Abstract
Macromolecular protein and peptide therapeutics have been proven to be effective in treating critical human diseases precisely. Thanks to biotechnological advancement, a huge number of proteins and peptide therapeutics were made their way to pharmaceutical market in past few decades. However, one of the biggest challenges to be addressed for protein therapeutics during clinical application is their fast degradation in serum and quick elimination owing to enzymatic degradation, renal clearance, liver metabolism and immunogenicity, attributing to the short half‐lives. Size and hydrophobicity of protein molecules make them prone to kidney filtration and liver metabolism. On the other hand, proteasomes responsible for protein destruction possess the capability of specifically recognizing almost all kinds of foreign proteins while avoiding any unwanted destruction of cellular components. At present almost all protein‐based drug formulations available in market are administered intravenously (IV) or subcutaneously (SC) with high dosing at frequent interval, eventually creating dose‐fluctuation‐related complications and reducing patient compliance vastly. Therefore, artificially increasing the therapeutic half‐life of a protein by attaching to it a molecule that increases the overall size (eg, PEG) or helps with receptor mediated recycling (eg, albumin), or manipulating amino acid chain in a way that makes it more prone towards aggregate formation, are some of the revolutionary approaches to avoid the fast degradation in vivo. Half‐life extension technologies that are capable of dramatically enhancing half‐lives of proteins in circulation (2–100 folds) and thus improving their overall pharmacokinetic (PK) parameters have been successfully applied on a wide range of protein therapeutics from hormones and enzymes, growth factor, clotting factor to interferon. The focus of the review is to assess the technological advancements made so far in enhancing circulatory half‐lives and improving therapeutic potency of proteins. Graphical abstract Figure. No Caption available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Abuchowski, A., van Es, T., Palczuk, N. C., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40291-2 · Cited by 1,358
Abuchowski, A., McCoy, J. R., Palczuk, N. C., van Es, T., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,274
Production of recombinant proteins by microbes and higher organisms
Demain, A. L., & Vaishnav, P. (2009) · Biotechnology Advances · doi:10.1016/j.biotechadv.2009.01.008 · Cited by 1,028
Albumin-based drug delivery: harnessing nature to cure disease
Larsen, M. T., Kuhlmann, M., Hvam, M. L., & Howard, K. A. (2016) · Molecular and Cellular Therapies · doi:10.1186/s40591-016-0048-8 · Cited by 683
PEGylation of therapeutic proteins
Jevševar, S., Kunstelj, M., & Porekar, V. G. (2010) · Biotechnology Journal · doi:10.1002/biot.200900218 · Cited by 681
Strategies to improve plasma half life time of peptide and protein drugs
Werle, M., & Bernkop-Schnürch, A. (2006) · Amino Acids · doi:10.1007/s00726-005-0289-3 · Cited by 660
Zarychanski, R., Abou-Setta, A. M., Turgeon, A. F., Houston, B. L., McIntyre, L., Marshall, J. C., & Fergusson, D. A. (2013) · JAMA · doi:10.1001/jama.2013.430 · Cited by 649
(2012) · Choice Reviews Online · doi:10.5860/choice.49-6264 · Cited by 578
Enhancement of therapeutic protein in vivo activities through glycoengineering
Elliott, S., Lorenzini, T., Asher, S., Aoki, K., Brankow, D., Buck, L., Busse, L., Chang, D., Fuller, J., Grant, J., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt799 · Cited by 510
Albumin as a versatile platform for drug half-life extension
Sleep, D., Cameron, J., & Evans, L. R. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.04.023 · Cited by 485
Albumin and its application in drug delivery
Sleep, D. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.993313 · Cited by 464
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
Strohl, W. R. (2015) · BioDrugs · doi:10.1007/s40259-015-0133-6 · Cited by 461
Treatment of Adenosine Deaminase Deficiency with Polyethylene Glycol–Modified Adenosine Deaminase
Hershfield, M. S., Buckley, R. H., Greenberg, M. L., Melton, A. L., Schiff, R., Hatem, C., Kurtzberg, J., Markert, M. L., Kobayashi, R. H., Kobayashi, A. L., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198703053161005 · Cited by 443
Schlapschy, M., Binder, U., Borger, C., Theobald, I., Wachinger, K., Kisling, S., Haller, D., & Skerra, A. (2013) · Protein Engineering Design and Selection · doi:10.1093/protein/gzt023 · Cited by 342
Pegaspargase: a review of clinical studies
Graham, M. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00110-8 · Cited by 322
Sand, K. M. K., Bern, M., Nilsen, J., Noordzij, H. T., Sandlie, I., & Andersen, J. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00682 · Cited by 304
Targeting proteins for degradation.
Schrader, E. K., Harstad, K. G., & Matouschek, A. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.250 · Cited by 287
Site-Specific PEGylation of Therapeutic Proteins
Dozier, J., & Distefano, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161025831 · Cited by 287
The Design and Development of Pegfilgrastim (PEG-rmetHuG-CSF, Neulasta®)
Molineux, G. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043452613 · Cited by 283
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics
Rath, T., Baker, K., Dumont, J. A., Peters, R. T., Jiang, H., Qiao, S.-W., Lencer, W. I., Pierce, G. F., & Blumberg, R. S. (2015) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2013.834293 · Cited by 281
Bendele, A. M., Seely, J., Richey, C., Sennello, G., & Shopp, G. M. (1998) · Toxicological Sciences · doi:10.1006/toxs.1997.2396 · Cited by 279
What is the future of PEGylated therapies?
Swierczewska, M., Lee, K. C., & Lee, S. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1113254 · Cited by 249
Santagostino, E., Martinowitz, U., Lissitchkov, T., Pan-Petesch, B., Hanabusa, H., Oldenburg, J., Boggio, L., Negrier, C., Pabinger, I., von Depka Prondzinski, M., et al. (2016) · Blood · doi:10.1182/blood-2015-09-669234 · Cited by 217
Levy, Y., Hershfield, M. S., Fernandez-Mejia, C., Polmar, S. H., Scudiery, D., Berger, M., & Sorensen, R. U. (1988) · The Journal of Pediatrics · doi:10.1016/s0022-3476(88)80271-3 · Cited by 215
Floss, D. M., Schallau, K., Rose-John, S., Conrad, U., & Scheller, J. (2010) · Trends in Biotechnology · doi:10.1016/j.tibtech.2009.10.004 · Cited by 206
Prolonged activity of factor IX as a monomeric Fc fusion protein
Peters, R. T., Low, S. C., Kamphaus, G. D., Dumont, J. A., Amari, J. V., Lu, Q., Zarbis-Papastoitsis, G., Reidy, T. J., Merricks, E. P., Nichols, T. C., et al. (2010) · Blood · doi:10.1182/blood-2009-08-239665 · Cited by 196
Half-life extended biotherapeutics
Kontermann, R. E. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1165661 · Cited by 191
Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers.
Hallaway, P. E., Eaton, J. W., Panter, S. S., & Hedlund, B. E. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10108 · Cited by 190
The use of PVP as a polymeric carrier to improve the plasma half-life of drugs
Kaneda, Y., Tsutsumi, Y., Yoshioka, Y., Kamada, H., Yamamoto, Y., Kodaira, H., Tsunoda, S.-I., Okamoto, T., Mukai, Y., Shibata, H., et al. (2004) · Biomaterials · doi:10.1016/j.biomaterials.2003.10.003 · Cited by 189
Half‐Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation
van Witteloostuijn, S. B., Pedersen, S. L., & Jensen, K. J. (2016) · ChemMedChem · doi:10.1002/cmdc.201600374 · Cited by 183
Bush, M. A., Matthews, J. E., De Boever, E. H., Dobbins, R. L., Hodge, R. J., Walker, S. E., Holland, M. C., Gutierrez, M., & Stewart, M. W. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00992.x · Cited by 181
Van Roy, M., Ververken, C., Beirnaert, E., Hoefman, S., Kolkman, J., Vierboom, M., Breedveld, E., ‘t Hart, B., Poelmans, S., Bontinck, L., et al. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0651-0 · Cited by 180
Protein–polymer conjugation — moving beyond PEGylation
Qi, Y., & Chilkoti, A. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2015.08.009 · Cited by 176
GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli
DeFrees, S., Wang, Z.-G., Xing, R., Scott, A. E., Wang, J., Zopf, D., Gouty, D. L., Sjoberg, E. R., Panneerselvam, K., Brinkman-Van der Linden, E. C. M., et al. (2006) · Glycobiology · doi:10.1093/glycob/cwl004 · Cited by 174
Glycosylation: impact, control and improvement during therapeutic protein production
Costa, A. R., Rodrigues, M. E., Henriques, M., Oliveira, R., & Azeredo, J. (2013) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2013.793649 · Cited by 173
Controlled Release of Insulin from Injectable Biodegradable Triblock Copolymer
Kim, Y. J., Choi, S., Koh, J. J., Lee, M., Ko, K. S., & Kim, S. W. (2001) · Pharmaceutical Research · doi:10.1023/a:1011074915438 · Cited by 172
Strategies to prolong the plasma residence time of peptidedrugs
Pollaro, L., & Heinis, C. (2010) · MedChemComm · doi:10.1039/c0md00111b · Cited by 161
Dextran prodrugs — structure and stability in relation to therapeutic activity
Larsen, C. (1989) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(89)90006-9 · Cited by 138
Choi, S., Baudyš, M., & Kim, S. W. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000026435.27086.94 · Cited by 137
Polysialylated insulin: synthesis, characterization and biological activity in vivo
Jain, S., Hreczuk-Hirst, D., McCormack, B., Mital, M., Epenetos, A. A., Laing, P., & Gregoriadis, G. (2003) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(03)00116-8 · Cited by 120
Polysialylated asparaginase: preparation, activity and pharmacokinetics
Fernandes, A. I., & Gregoriadis, G. C. (1997) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(97)00056-3 · Cited by 114
Fc-Based Cytokines: Prospects for Engineering Superior Therapeutics
Jazayeri, J. A., & Carroll, G. J. (2008) · BioDrugs · doi:10.2165/00063030-200822010-00002 · Cited by 113
Kong, Z., Qin, P., Xiao, S., Zhou, H., Li, H., Yang, R., Liu, X., Luo, J., Li, Z., Ji, G., et al. (2017) · Blood · doi:10.1182/blood-2017-01-761262 · Cited by 112
Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates
Mancuso, M. E., & Santagostino, E. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6040039 · Cited by 110
Controlled Release of Insulin from Injectable Biodegradable Triblock Copolymer Depot in ZDF Rats
Choi, S., & Kim, S. W. (2003) · Pharmaceutical Research · doi:10.1023/b:pham.0000008050.99985.5c · Cited by 109
Hyperglycosylated hCG, a review
Cole, L. A. (2010) · Placenta · doi:10.1016/j.placenta.2010.06.005 · Cited by 108
Gaspar, H. B. (2009) · Biologics · doi:10.2147/btt.s3103 · Cited by 104
Cook, D. M., Biller, B. M. K., Vance, M. L., Hoffman, A. R., Phillips, L. S., Ford, K. M., Benziger, D. P., Illeperuma, A., Blethen, S. L., Attie, K. M., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020480 · Cited by 93
Edwards, C. K. (1999) · Annals of the Rheumatic Diseases · doi:10.1136/ard.58.2008.i73 · Cited by 90
Half‐life extended factor VIII for the treatment of hemophilia A
Tiede, A. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12929 · Cited by 87
Noga, M., Edinger, D., Kläger, R., Wegner, S. V., Spatz, J. P., Wagner, E., Winter, G., & Besheer, A. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.12.025 · Cited by 87
Novel long-lasting interferon alpha derivatives designed by glycoengineering
Ceaglio, N., Etcheverrigaray, M., Kratje, R. B., & Oggero, M. (2007) · Biochimie · doi:10.1016/j.biochi.2007.10.013 · Cited by 87
Selective conjugation of poly(2-ethyl 2-oxazoline) to granulocyte colony stimulating factor
Mero, A., Fang, Z., Pasut, G., Veronese, F. M., & Viegas, T. X. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.02.025 · Cited by 80
Polymers for Protein Conjugation
Pasut, G. (2014) · Polymers · doi:10.3390/polym6010160 · Cited by 78
Arvedson, T., O’Kelly, J., & Yang, B. (2015) · BioDrugs · doi:10.1007/s40259-015-0127-4 · Cited by 76
Liebner, R., Mathaes, R., Meyer, M., Hey, T., Winter, G., & Besheer, A. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.03.010 · Cited by 74
Development of therapeutic proteins: advances and challenges
Akash, M. S. H., Rehman, K., TARIQ, M., & Chen, S. (2015) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-1411-8 · Cited by 67
N-Glycosylation Increases the Circulatory Half-Life of Human Growth Hormone
Flintegaard, T. V., Thygesen, P., Rahbek-Nielsen, H., Levery, S. B., Kristensen, C., Clausen, H., & Bolt, G. R. (2010) · Endocrinology · doi:10.1210/en.2010-0574 · Cited by 61
Trujillo, J. M., & Nuffer, W. A. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014545807 · Cited by 58
AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer.
Neal, J. W., & Wakelee, H. A. (2010) · PubMed · Cited by 52
Oral Delivery of Glucagon-like Peptide-1 and Analogs: Alternatives for Diabetes Control?
Araújo, F., Fonte, P., Santos, H. A., & Sarmento, B. F. C. C. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600630 · Cited by 51
Yuen, K. C. J., Conway, G. S., POPOVIC, V. M., Merriam, G. R., Bailey, T. S., Hamrahian, A. H., Biller, B. M. K., Kipnes, M. S., Moore, J. A., Humphriss, E., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1437 · Cited by 49
Spears, B. R., Waksal, J., McQuade, C., Lanier, L., & Harth, E. M. (2013) · Chemical Communications · doi:10.1039/c3cc38369e · Cited by 47
Rasmussen, M. H., Bysted, B. V., Anderson, T. W., Klitgaard, T., & Madsen, J. C. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2813 · Cited by 40
A biosynthetic route for polysialylating proteins in Escherichia coli
Keys, T. G., Wetter, M., Hang, I., Rutschmann, C., Russo, S., Mally, M., Steffen, M., Zuppiger, M., Müller, F., Schneider, J., et al. (2017) · Metabolic Engineering · doi:10.1016/j.ymben.2017.10.012 · Cited by 37
DeAngelis, P. L. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.978282 · Cited by 33
VE-cadherin increases the half-life of VEGF receptor 2
Calera, M. R., Venkatakrishnan, A., & Kazlauskas, A. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.07.007 · Cited by 31
Murray, J. E., Laurieri, N., & Delgoda, R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802104-0.00024-x · Cited by 30
Powell, J., & Gurk‐Turner, C. (2002) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2002.11927861 · Cited by 29
Wang, Y., Shao, J., Zaro, J. L., & Shen, W. (2013) · Diabetes · doi:10.2337/db13-0973 · Cited by 28
Jurado, J. M., Sánchez, E. T., Olmos, D., & Alba, E. (2007) · Clinical & Translational Oncology · doi:10.1007/s12094-007-0128-y · Cited by 27
Developing long‐acting growth hormone formulations
Cawley, P., Wilkinson, I., & Ross, R. J. M. (2013) · Clinical Endocrinology · doi:10.1111/cen.12240 · Cited by 25
Nanocrystals Technology for Pharmaceutical Science
Cheng, Z., Lian, Y., Kamal, Z., Ma, X., Chen, J., Zhou, X., Su, J. Y., & Qiu, M. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666180518082420 · Cited by 21
Do, B. H., Kang, H. J., Song, J.-A., Nguyen, M. T., Park, S., Yoo, J., Nguyen, A. N., Kwon, G. G., Jang, J., Jang, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-06726-7 · Cited by 19
Carrier Mediated Systemic Delivery of Protein and Peptide Therapeutics
Zaman, R., Othman, I., & Chowdhury, E. H. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160720145328 · Cited by 18
Self-citationKe, S., Wright, J. C., & Kwon, G. S. (2007) · Bioconjugate Chemistry · doi:10.1021/bc700182t · Cited by 10
Fusion Proteins for Half‐Life Extension
Schmidt, S. R. (2013) · Wiley eBooks · doi:10.1002/9781118354599.ch6 · Cited by 7
Cited by
Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
Madden, S. K., de Araujo, A. D., Gerhardt, M., Fairlie, D. P., & Mason, J. M. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01291-6 · Cited by 397
Xu, G., Jin, J., Fu, Z., Wang, G., Lei, X., Xu, J., & Wang, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02312-w · Cited by 269
Aggregation of Protein Therapeutics Enhances Their Immunogenicity: Causes and Mitigation Strategies
Lundahl, M. L. E., Fogli, S., Colavita, P. E., & Scanlan, E. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00067e · Cited by 212
Rational Design of Potent Peptide Inhibitors of the PD-1:PD-L1 Interaction for Cancer Immunotherapy
Yin, H., Zhou, X., Huang, Y.-H., King, G. J., Collins, B. M., Gao, Y., Craik, D. J., & Wang, C. K. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c08132 · Cited by 57
Metadata
- Authors
- Zaman, R., Islam, R. A., Ibnat, N., Othman, I., Zaini, A., Lee, C. Y., & Chowdhury, E. H.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 301
- Pages
- 176-189
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2920526722
- Cited by
- 278
- References
- 79
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.